MELBOURNE, March 11, 2026, 09:36 AEDT (Time and Date) CSL Limited said it had broken ground on a $1.5 billion expansion of its Kankakee, Illinois, manufacturing site, deepening a bet on the business management needs to lift growth. The buildout is aimed at boosting output of plasma-derived therapies — medicines made from proteins in human blood plasma — and is due to be operational by 2031, with at least 300 new pharmaceutical roles. (Global Newsroom | CSL) The timing matters. Last month, CSL posted an 81% drop in first-half net profit, booked heavy impairments and put Gordon Naylor in the